In the previous sections, we have also discussed the upregulation of interleukins in T2DM patients and specifically of IL-1β, which has been reported to increase the resistance of MCF-7 (ER+ cells) to tamoxifen [203], doxorubicin [204] and cisplatin [205]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.